# Rezafungin as Primary Prophylaxis of Pneumocystis jirovecii Pneumonia in a Critically Ill Person Presenting with AIDS with Trimethoprim/Sulfamethoxazole Allergy: A Case Report

**Authors:** Martina Bottanelli, Alice Mulè, Chiara Molteni, Martina Gerbi, Mauro Pietro Zago, Sara Volpi, Sofia Pettenuzzo, Alessandro Pandolfo, Valentina Morena, Nicole Gemignani, Michele Fogliata, Federico Conti, Alessandra Consonni, Lucia Bradanini, Silvia Pontiggia, Stefania Piconi

PMC · DOI: 10.3390/jof12030189 · Journal of Fungi · 2026-03-05

## TL;DR

A patient with AIDS and a TMP-SMX allergy successfully used rezafungin to prevent Pneumocystis jirovecii pneumonia, suggesting it could be a viable alternative when standard drugs are unavailable.

## Contribution

This is the first reported case of rezafungin used as PCP prophylaxis in a person with HIV.

## Key findings

- Rezafungin was used successfully as PCP prophylaxis in a PWH with a TMP-SMX allergy.
- No adverse events or fungal infections occurred during rezafungin use.
- The case highlights rezafungin as a potential alternative when standard prophylactic agents are contraindicated.

## Abstract

Primary prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in people with HIV (PWH) and CD4+ counts <200 cells/µL using trimethoprim/sulfamethoxazole (TMP-SMX) is highly effective but often poorly tolerated. Alternative agents may have limited efficacy or availability. Although rezafungin demonstrated PCP protection comparable to TMP-SMX in animal models, human data are limited to the ongoing ReSPECT trial, and evidence in PWH is lacking. We report the first use of rezafungin as PCP prophylaxis in a PWH. A 43-year-old man presenting with AIDS (HIV-RNA 8.48 × 106 copies/mL; CD4+ 20 cells/µL) was admitted with disseminated tuberculosis and multiple bowel perforations requiring urgent surgery. The postoperative course was marked by infectious and surgical complications. Antitubercular therapy and TMP-SMX prophylaxis were initiated postoperatively, followed by antiretroviral therapy (ART). Later, TMP-SMX was discontinued due to hypersensitivity. Because drug–drug interactions precluded atovaquone or dapsone and pentamidine was unavailable, rezafungin was started. No adverse events or fungal breakthrough infections occurred despite abdominal complications. Further data are needed to determine whether rezafungin represents a viable prophylactic option when standard agents are contraindicated or unavailable.

## Linked entities

- **Chemicals:** trimethoprim/sulfamethoxazole (PubChem CID 358641), rezafungin (PubChem CID 78318119), atovaquone (PubChem CID 74989), dapsone (PubChem CID 2955), pentamidine (PubChem CID 4735)
- **Diseases:** Pneumocystis jirovecii pneumonia (MONDO:0019121), AIDS (MONDO:0012268), disseminated tuberculosis (MONDO:0005848)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** cryptococcal meningitis (MESH:D016919), hepatitis C (MESH:D019698), lymphadenopathy (MESH:D008206), viremia (MESH:D014766), abdominal complications (MESH:D000007), necrosis (MESH:D009336), aspergillosis (MESH:D001228), erythematous rash (MESH:D005076), Infectious Diseases (MESH:D003141), septic (MESH:D001170), critically ill (MESH:D016638), invasive candidiasis (MESH:D058365), eosinophilia (MESH:D004802), fever (MESH:D005334), PCP (MESH:D011020), diarrhea (MESH:D003967), HD (MESH:D003428), CNS (MESH:D002493), Invasive (MESH:D009361), inflammation (MESH:D007249), hematological and renal toxicity (MESH:D006402), CMV (MESH:D003586), bowel perforations (MESH:D057112), allergy (MESH:D004342), granulomatous (MESH:D013968), AIDS (MESH:D000163), P. jirovecii (MESH:D016720), gastrointestinal perforation (MESH:D005767), TB (MESH:D014390), respiratory failure (MESH:D012131), frailty (MESH:D000073496), toxoplasmosis (MESH:D014123), hepatitis B (MESH:D006509), infection (MESH:D007239), Syphilis (MESH:D013587), HIV (MESH:D015658), septic shock (MESH:D012772), hepatic toxicity (MESH:D056486), injury to (MESH:D014947), condition (MESH:D020763), opportunistic infections (MESH:D009894), fungal invasive candidiasis (MESH:D000072742), intestinal malabsorption (MESH:D008286), weight loss (MESH:D015431), M. tuberculosis (MESH:D014376), bacterial and (MESH:D001424), Fungal Diseases (MESH:D009181), ill (MESH:D002908)
- **Chemicals:** ethambutol (MESH:D004977), galactomannan (MESH:C012990), fluconazole (MESH:D015725), tigecycline (MESH:D000078304), DTG (MESH:C562325), posaconazole (MESH:C101425), caspofungin (MESH:D000077336), rifabutin (MESH:D017828), TMP-SMX (MESH:D015662), pentamidine (MESH:D010419), dapsone (MESH:D003622), ceftazidime (MESH:D002442), azoles (MESH:D001393), Rezafungin (MESH:C000629634), atovaquone (MESH:D053626), meropenem (MESH:D000077731), HD (-), methicillin (MESH:D008712), tenofovir alafenamide (MESH:C442442), isoniazid (MESH:D007538), ganciclovir (MESH:D015774), anidulafungin (MESH:D000077612), piperacillin/tazobactam (MESH:D000077725), vancomycin (MESH:D014640), pyrazinamide (MESH:D011718), Echinocandins (MESH:D054714), rifampicin (MESH:D012293), pyrimethamine (MESH:D011739)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Homo sapiens (human, species) [taxon 9606], Enterococcus faecium (species) [taxon 1352], Candida albicans (species) [taxon 5476], Toxoplasma gondii (species) [taxon 5811], Enterobacter cloacae (species) [taxon 550], Staphylococcus aureus (species) [taxon 1280], Mus musculus (house mouse, species) [taxon 10090], Pneumocystis jirovecii (species) [taxon 42068], Human immunodeficiency virus 1 (no rank) [taxon 11676], Mycobacterium tuberculosis complex (species group) [taxon 77643]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028464/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13028464/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028464/full.md

---
Source: https://tomesphere.com/paper/PMC13028464